For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Experimental drug Obicetrapib reduces LDL cholesterol and hard-to-treat lipoprotein (a) levels in heart disease patients, potentially providing a new tool against heart disease.

For people with advanced heart failure, left ventricular assist devices, or LVADs, can be a literal lifesaver.

Optimized treatment reduces the mortality risk associated with chronic heart failure, leading to improvements in both longevity and quality of life.

Tirzepatide improves kidney function and reduces cardiovascular risks in patients with obesity, chronic kidney disease, and heart failure with preserved ejection fraction.

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction compared with placebo at one year, according to ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart ...